JP Morgan Chase’s PTC Therapeutics PTCT Stock Holding History

JP Morgan Chase’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.77M	Hold	27,000	–	–	﹤0.01%	4203
2025 Q4	$2.05M	Buy	+27,000	New	+$1.96M	﹤0.01%	4053
2025 Q2	–	Sell	-84,000	Closed	-$4.28M	–	7520
2025 Q1	$4.28M	Buy	84,000 +30,000	+56%	+$1.5M	﹤0.01%	3289
2024 Q4	$2.44M	Buy	+54,000	New	+$2.31M	﹤0.01%	3996
2018 Q4	–	Sell	-97,100	Closed	-$4.56M	–	5885
2018 Q3	$4.56M	Buy	+97,100	New	+$4.02M	﹤0.01%	2811
2018 Q2	–	Sell	-45,000	Closed	-$1.22M	–	5660
2018 Q1	$1.22M	Sell	45,000 -115,000	-72%	-$2.91M	﹤0.01%	3566
2017 Q4	$2.67M	Buy	+160,000	New	+$2.71M	﹤0.01%	3138

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

JP Morgan Chase's PTCT Position: Q1 2026 in Review

JP Morgan Chase reduced its PTC Therapeutics (PTCT) stake by 2.8% in Q1 2026, selling an estimated $710K and leaving 346,017 shares worth $22.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

JP Morgan Chase first reported a position in PTCT in Q3 2014 and has held it in 44 quarters since. The position peaked at $42.1M in Q1 2023. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

JP Morgan Chase held 346,017 shares of PTC Therapeutics worth $22.7M as of Q1 2026.
JP Morgan Chase sold 10,024 PTC Therapeutics shares in Q1 2026, an estimated $710K.
PTC Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1975 holding.
JP Morgan Chase first reported a position in PTC Therapeutics in Q3 2014 and has held it in 44 quarters since.
JP Morgan Chase's PTC Therapeutics position peaked at $42.1M in Q1 2023.
350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.